Pharmaxis Of Australia Readies Europe Application For Bronchitol
This article was originally published in PharmAsia News
Australia's Pharmaxis says it is ready to apply for approval of its Bronchitol (mannitol) dry powder to treat cystic fibrosis in Europe. The company said it was acting on the basis of positive returns from a Phase III trial in Europe. The drug is intended to reduce mucus build-up in the lungs of patients with chronic respiratory problems. Pharmaxis also is recruiting participants for a U.S. trial. (Click here for more
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
With Roche's oral spinal muscular atrophy therapy Evrysdi off to a strong start after its recent US launch, Novartis is switching its priorities for rival RNA-splicing drug branaplam and putting it into a Phase IIb trial for Huntington's disease.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.